Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

BACKGROUND: Osteoprotegerin (OPG) is a tumour and/or bone derived factor that may protect tumour cells from apoptosis. In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated...

Bibliografski detalji
Glavni autori:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Format:	Journal article
Jezik:	English
Izdano:	2004

Slični predmeti

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
od: Eaton, C, i dr.
Izdano: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
od: Holen, I, i dr.
Izdano: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
od: Holen, I, i dr.
Izdano: (2002)

Role of osteoprotegerin (OPG) in cancer.
od: Holen, I, i dr.
Izdano: (2006)

The role of osteoprotegerin in breast and prostate cancer
od: Holen, I, i dr.
Izdano: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
od: Holen, I, i dr.
Izdano: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
od: Miles, L, i dr.
Izdano: (2004)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
od: Gamal B Mohamed, i dr.
Izdano: (2011-01-01)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
od: Holen Ingunn, i dr.
Izdano: (2009-07-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
od: Lili Zhang, i dr.
Izdano: (2016-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
od: Riham Eid, i dr.
Izdano: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
od: Indra Wijaya, i dr.
Izdano: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
od: Croucher, P, i dr.
Izdano: (2000)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
od: Saba Tariq, i dr.
Izdano: (2022-02-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
od: Shipman, C, i dr.
Izdano: (2002)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
od: Siamak Kazemi-Sufi, i dr.
Izdano: (2024-09-01)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
od: Shipman, C, i dr.
Izdano: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
od: Shipman, C, i dr.
Izdano: (2002)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
od: Noura N. Alraouji, i dr.
Izdano: (2024-08-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
od: Chan Kai-Ming, i dr.
Izdano: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
od: Syed Muhammad Muneeb Akhtar, i dr.
Izdano: (2024-07-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
od: Waterman, E, i dr.
Izdano: (2007)

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
od: Alice Wang, i dr.
Izdano: (2021-07-01)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
od: Cheema, Raheem Ramzan
Izdano: (2021)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
od: Yao Jing, i dr.
Izdano: (2011-03-01)

Changes of serum osteoprotegerin level in recurrent urolithiasis
od: A. V. Savilov, i dr.
Izdano: (2023-10-01)

Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?
od: Hamdy, F
Izdano: (2005)

Osteoprotegerin and the development of myeloma bone disease
od: Croucher, P, i dr.
Izdano: (2004)

Dickkopf-1 levels and serum Osteoprotegerin in women with Osteoporosis
od: Mehrzad Hajialilo, i dr.
Izdano: (2013-12-01)

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations
od: Veselina Goranova-Marinova, i dr.
Izdano: (2007-07-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
od: Martin Widschwendter, i dr.
Izdano: (2015-10-01)

Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
od: Yan Zhao, i dr.
Izdano: (2023-07-01)

Rapid Androgen-Responsive Proteome Is Involved in Prostate Cancer Progression
od: Jong-Kwang Kim, i dr.
Izdano: (2021-12-01)

The influence of vitamin D administration on the clinical presentation, body mass index, and osteoprotegerin (OPG) level in a sample of Egyptian children with familial Mediterranean fever
od: Hanaa Reyad Abdallah, i dr.
Izdano: (2021-12-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
od: F. F. Rija, i dr.
Izdano: (2021-10-01)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
od: Yen-Liang Chen, i dr.
Izdano: (2023-10-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
od: Yosra Azizpour, i dr.
Izdano: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
od: Yosra Azizpour, i dr.
Izdano: (2020-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
od: Croucher, P, i dr.
Izdano: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
od: Croucher, P, i dr.
Izdano: (2001)